Antigenics News

With Antigenics back in the news after the EMEA officially recommended against approving the company's kidney cancer vaccine in Europe - followed by the subsequent withdrawal of the approval application by Antigenics - a few readers of VFC's Stock House have requested comment.

Antigenics Inc. announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has formally adopted a negative opinion on the marketing authorization application for Oncophage as a treatment in earlier-stage, localized renal cell carcinoma .

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has formally adopted a negative opinion on the marketing authorization application for Oncophage as a treatment in earlier-stage, localized renal cell carcinoma .

Antigenics Inc. filed Quarterly Report for the period ended 2009-09-30. Antigenics Inc.

Antigenics October 29, 2009 11:00 AM ET Executives Shalini Sharp - Chief Financial Officer and Vice President Dr.

Our analysts have issued complimentary analysis on the following six companies: Seattle Genetics Inc.

Below is a 10-stock BioMed Momentum Index that I have created along with related financial data from Google Finance as of 10/28/09, including the stock price, 52-week change, average daily trading volume, and market cap.

News that the European advisory committee will adopt a negative opinion next month on Antigenics' kidney cancer vaccine candidate, Oncophage, not only hurt their shares by 42% Wednesday, but raised questions over where the biotech company can go from here.

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco , has presented an update on a Phase 2 clinical trial of Oncophage for recurrent high grade glioma at the 2009 Joint Meeting of SNO and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

Drug developer Antigenics Inc. said researchers at the University of California , San Francisco, reported positive results stemming from a study using its cancer therapy Oncophage to treat brain-cancer patients.

In an early Wednesday press release, Antigenics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has verbally notified the company that a negative vote should be anticipated in November, when the European regulators will meet to officially cast their votes.

On 6/1/09, Antigenics announced results of an interim analysis from the Company's ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46% lower risk of death when treated with Oncophage cancer vaccine compared with observation .

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use , of the European Medicines Agency , has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application for Oncophage in early-stage, localized renal cell carcinoma .

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use , of the European Medicines Agency , has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application for Oncophage in early-stage, localized renal cell carcinoma .

Drug stocks were mildly mixed in morning trading Wednesday as shares of Genzyme Corp.

Investors seeking free and unbiased analyst opinions on the companies mentioned in this release are encouraged to register at http://www.thefortunefinancial.com/ for a free subscription to access these reports.

In an absolutely boring trading day, there were a few stocks that were worthy of mention on Monday: CPST : Capstone Turbine, the maker of low-emission microturbine energy systems, opened the trading week by releasing news that the company has received $3 million in follow-on orders from two of its large oil & gas customers; Aquatec-Maxcon Pty Ltd ...

That's good news for investors who have long been interested in this promising sub-sector of the healthcare markets.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.